Preclinical activity of the antibody‐drug conjugate denintuzumab mafodotin (SGN‐CD19A) against pediatric acute lymphoblastic leukemia xenografts

ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies

(2018) Francesca Zammarchi et al.   BLOOD

Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia

(2017) Swapna Thota et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Genetic Basis of Acute Lymphoblastic Leukemia

(2017) Ilaria Iacobucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement

(2017) Annabelle Zoghbi et al.   PEDIATRIC BLOOD & CANCER

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

(2016) R. Gardner et al.   BLOOD

A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   Clinical Lymphoma Myeloma & Leukemia

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors

(2016) I Aldoss et al.   LEUKEMIA

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy

(2016) Ahmad Rayes et al.   PEDIATRIC BLOOD & CANCER

Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies

(2016) Marco Ruella et al.   Computational and Structural Biotechnology Journal

Blinatumomab

(2015) Larry W. Buie et al.   ANNALS OF PHARMACOTHERAPY

Monoclonal antibodies in acute lymphoblastic leukemia

(2015) E. Jabbour et al.   BLOOD

Effective Targeting of the P53-MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia

(2015) J. Richmond et al.   CLINICAL CANCER RESEARCH

FDA Approval: Blinatumomab

(2015) D. Przepiorka et al.   CLINICAL CANCER RESEARCH

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

(2015) Ching-Hon Pui et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute Lymphoblastic Leukemia in Children

(2015) Stephen P. Hunger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

(2015) E. Sotillo et al.   Cancer Discovery

Declining childhood and adolescent cancer mortality

(2014) Malcolm A. Smith et al.   CANCER

Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts

(2014) S. Suryani et al.   CLINICAL CANCER RESEARCH

Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia

(2014) Caroline Le Jeune et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia

(2014) S. Suryani et al.   MOLECULAR CANCER THERAPEUTICS

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody Therapy for Pediatric Leukemia

(2014) Aditi Vedi et al.   Frontiers in Oncology

Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug

(2013) J. M. Rowe et al.   BLOOD

The Anti-CD19 Antibody-Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia

(2013) H. Carol et al.   CLINICAL CANCER RESEARCH

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

(2013) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER

How I treat relapsed childhood acute lymphoblastic leukemia

(2012) F. Locatelli et al.   BLOOD

Pharmacokinetic Modeling of an Induction Regimen for In Vivo Combined Testing of Novel Drugs against Pediatric Acute Lymphoblastic Leukemia Xenografts

(2012) Barbara Szymanska et al.   PLoS One

Investigational antibody-drug conjugates for hematological malignancies

(2010) Andrew G Polson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

(2010) P. J. Houghton et al.   MOLECULAR CANCER THERAPEUTICS

CD19: a promising B cell target for rheumatoid arthritis

(2009) Thomas F. Tedder   Nature Reviews Rheumatology

Differential Cellular Internalization of Anti-CD19 and -CD22 Immunotoxins Results in Different Cytotoxic Activity

(2008) X. Du et al.   CANCER RESEARCH

Approved monoclonal antibodies for cancer therapy

(2008) Michael Boyiadzis et al.   EXPERT OPINION ON BIOLOGICAL THERAPY